PrxII Cancer Research Results

PrxII, Peroxiredoxin II: Click to Expand ⟱
Source:
Type:
Prx II is a peroxidase that reduces hydrogen peroxide and organic hydroperoxides. Higher levels of Prx II in cancer cells enhance their ability to detoxify reactive oxygen species (ROS).
• This protection against oxidative damage enables tumor cells to survive in a stressful microenvironment characterized by high metabolic activity and inflammation.
Prx II is often upregulated in several types of cancers. For example, increased expression of Prx II has been reported in breast, lung, colorectal, and gastric cancers, among others. This upregulation is generally viewed as an adaptive response of cancer cells to the increased oxidative stress associated with rapid proliferation and a hostile tumor microenvironment.
- Higher Prx II expression has been associated with unfavorable clinical outcomes.

• Many cancer therapies, including chemotherapy and radiation therapy, rely on the generation of ROS to induce cancer cell death. Elevated levels of Prx II can reduce the efficacy of these treatments by neutralizing ROS, thereby contributing to resistance.
Pca, Prostate Cancer: Click to Expand ⟱
Prostate Cancer: Alterations in genes such as ERG, SPOP, MYC, androgen receptor (AR), and CHD1, drive PCa progression.
TP53 is the most commonly mutated gene in human cancer.
HH↑, GLI-1↑, SHH↑ P53↓
The loss of p53 and/or other tumor suppressor genes, reduced capacity for DNA repair, the dysfunction of telomerase activity, and changes in the pathways that govern the growth of cells also mediate the progression of Pca.
It has been well documented that Ca2+ influx and MDR1 upregulation are highly associated with GEM metabolism in human pancreatic carcinoma.
Increased Growth factor IGF-1/IGF-1R axis activation mediated by both PI3K/Akt or RAF/MEK/ERK system and AR expression remains important in the development and progression of prostate cancer.
It has been demonstrated that prostate cancer cells are relatively sensitive to heat stress.
Long non-coding RNA MALAT1 has been reported as an oncogenic target in multiple types of cancers, including PC.
Scientific Papers found: Click to Expand⟱
68- QC,  BaP,    Differential protein expression of peroxiredoxin I and II by benzo(a)pyrene and quercetin treatment in 22Rv1 and PrEC prostate cell lines
- in-vitro, Pca, 22Rv1 - in-vitro, Pca, PrEC
PrxI∅, PrxII∅, *toxicity↓, ROS↓, ROS↑, ROS∅, chemoP↑, PrxII↑, i-H2O2↓,

Showing Research Papers: 1 to 1 of 1

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 1

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress ⓘ

i-H2O2↓, 1,   PrxI∅, 1,   PrxII↑, 1,   PrxII∅, 1,   ROS↓, 1,   ROS↑, 1,   ROS∅, 1,  

Functional Outcomes ⓘ

chemoP↑, 1,  
Total Targets: 8

Pathway results for Effect on Normal Cells:


Functional Outcomes ⓘ

toxicity↓, 1,  
Total Targets: 1

Scientific Paper Hit Count for: PrxII, Peroxiredoxin II
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:22  Cells:%  prod#:%  Target#:1085  State#:%  Dir#:6
  wNotes=0  sortOrder:rid,rpid

 

Home Page